Merz triples debut Schuldschein to €450m as its healthcare funding base expands

The Merz Group, whose family-owned parent is Merz Holding GmbH & Co. KG, has completed its inaugural Schuldschein loan with a final volume of €450 million. The transaction was launched at €150 million before investor demand allowed Merz to triple the amount, with the proceeds settled and paid to the company on July 16. The financing combines fixed- and floating-rate tranches maturing over three, five, seven and ten years, giving Merz a new source of medium- and long-term capital. It complements the group’s syndicated bank financing and creates additional capacity for organic investment and acquisitions. However, Merz has not disclosed the all-in borrowing cost, tranche allocations, current leverage or specific use of proceeds, leaving the economic return on the new debt as the central unresolved question.

How did Merz turn a €150 million debut Schuldschein into a €450 million financing?

Merz entered the Schuldschein market with an initial transaction size of €150 million. The final placement reached €450 million, while the company described the book as more than three times oversubscribed relative to the original launch volume.

Approximately 50 German and international investors participated. They included private banks, German state-owned regional banks, public savings banks, cooperative banks, pension funds and occupational pension institutions.

That breadth matters because the transaction does more than increase available capital. It creates direct relationships with a new group of institutional creditors that could support future Schuldschein placements or other private-debt transactions.

The inclusion of a ten-year tranche is particularly notable. Longer maturities expose lenders to more uncertainty around strategy, operating performance and interest rates. The willingness of some investors to commit capital for ten years indicates comfort with Merz as a long-term borrower, although the company did not disclose the size or pricing of that tranche.

BNP Paribas and DZ BANK arranged the transaction. Hogan Lovells Cadwalader advised the Merz Pharma Group on the legal aspects.

Why does the Schuldschein diversify Merz Group funding beyond syndicated bank loans?

A Schuldschein is a privately placed German-law loan instrument that combines characteristics of conventional bank lending and debt capital markets financing. It can accommodate multiple lenders, maturities and interest-rate structures without requiring an exchange listing or public bond prospectus.

For Merz, the main strategic benefit is funding diversification. The group previously relied on syndicated financing arrangements, which concentrate relationships within a defined bank group. The Schuldschein adds private banks, regional banks, savings institutions and pension investors to the creditor base.

This reduces dependence on any single funding channel. If syndicated lending conditions tighten, Merz will have an established alternative route to institutional capital. Conversely, retaining syndicated facilities gives the company flexibility if Schuldschein pricing becomes less attractive.

The format also suits a private, family-owned healthcare group that does not have publicly traded equity. It provides access to debt investors without requiring the disclosure framework, public credit rating or secondary-market infrastructure normally associated with a bond.

The benefit is not absolute. A wider creditor base can make future amendments or restructurings more complex because Schuldschein investments generally involve bilateral lender relationships. Diversification improves access to capital, but it also increases the number of financial stakeholders whose interests must be managed.

What does the sub-100-basis-point five-year spread reveal about confidence in Merz?

Merz reported a credit spread of less than 100 basis points on the five-year benchmark tranche. This is the premium investors required for Merz-specific credit risk above the relevant underlying benchmark.

The result indicates competitive demand for the five-year portion of the transaction. Combined with the oversubscription and participation across four maturities, it suggests that lenders viewed Merz as an attractive private healthcare credit.

The spread should not be confused with the final interest rate. The all-in cost also depends on the benchmark interest rate or swap curve, whether the tranche is fixed or floating, transaction fees and the timing of interest payments.

Merz has not disclosed the final coupons, the proportion assigned to fixed- and floating-rate tranches or the weighted average cost of the overall €450 million. Public readers therefore cannot calculate the annual interest expense created by the transaction.

The investor response nevertheless carries particular significance because Merz is privately owned. There is no publicly traded share price or corporate bond spread through which the market continuously evaluates the group. The Schuldschein pricing and demand provide a rare external indication of institutional confidence, even if investors may have received more financial information than Merz has made public.

How could the funding support growth across Merz Aesthetics and Merz Therapeutics?

Merz said the financing would support future organic and inorganic growth, but it did not allocate the proceeds to individual businesses or projects.

The group’s three largest healthcare operations are Merz Aesthetics, Merz Therapeutics and Merz Lifecare. Their capital requirements differ substantially, creating several possible uses for the new funding.

Merz Aesthetics operates across injectables, medical devices and skincare. Organic deployment could include clinical development, regulatory work, manufacturing, market launches and geographic expansion. Acquisitions could add complementary products, technologies or distribution capabilities.

Merz Therapeutics is focused primarily on specialty neurology and has explicitly identified partnerships and acquisitions as components of its growth strategy. In 2024, it paid $185 million for INBRIJA and (F)AMPYRA and related assets from Acorda Therapeutics, expanding into Parkinson’s disease and multiple sclerosis.

Following that transaction, Merz Therapeutics invested in commercial infrastructure, patient access, supply chains and international distribution. That history demonstrates how an acquisition can require additional capital after the purchase price has been paid.

Merz Lifecare, which owns consumer healthcare brands including tetesept, Merz Spezial, SOS and Zirkulin, presents a different set of opportunities. Investment could support brand expansion, product development, distribution or consolidation within consumer health.

The financing therefore provides strategic optionality across the portfolio. It does not, however, prove that Merz has identified acquisitions capable of earning returns above the cost of the new debt.

Why does Merz Group’s approximately €2.5 billion revenue base matter for the new debt?

Merz reported approximately €2.5 billion of revenue in its latest fiscal year and employs more than 5,500 people worldwide. The €450 million Schuldschein is equivalent to about 18% of annual revenue, making it a meaningful financing event rather than a routine liquidity adjustment.

That comparison is not a leverage ratio. Revenue does not reveal operating profit, cash conversion, existing debt or the company’s ability to service interest and principal. A proper credit assessment would require EBITDA, operating cash flow, net debt, lease obligations and maturity information.

The available figures nevertheless indicate that Merz has continued expanding. In October 2025, the company described annual revenue as exceeding €2.2 billion and employment as exceeding 5,000. The latest announcement places revenue at approximately €2.5 billion and employment above 5,500.

Because the group is privately owned, detailed financial statements and guidance are not presented with the frequency expected from a listed company. This makes the Schuldschein’s scale and pricing useful signals, but they cannot substitute for balance-sheet transparency.

The transaction increases financial flexibility while also creating fixed repayment obligations. Its strategic value will depend on whether Merz’s earnings and cash generation grow faster than its financing costs.

What interest-rate and refinancing risks remain behind the limited disclosure?

The division between fixed- and floating-rate debt will influence Merz’s future interest expense. Fixed-rate tranches provide cost certainty, while floating-rate tranches can become cheaper if benchmark rates fall but more expensive if rates rise.

Merz has not disclosed this mix, preventing an assessment of its interest-rate sensitivity. It also has not stated whether it has used derivatives to hedge the floating-rate exposure.

The maturity ladder is a clear strength because the debt is spread across four periods rather than concentrated on a single repayment date. The three-, five-, seven- and ten-year maturities should reduce refinancing concentration if the individual tranches are reasonably balanced.

The amounts assigned to each maturity remain undisclosed. A heavily concentrated five-year tranche, for example, would create a larger refinancing requirement than an evenly distributed structure.

The company has also not published its net debt, leverage covenants, security arrangements or the current size and utilisation of its syndicated financing. Oversubscription demonstrates market access, but it does not independently establish that leverage is low or that the proceeds will be deployed conservatively.

How does the Schuldschein change Merz Group’s capacity for healthcare acquisitions?

The most important strategic effect is that Merz now has €450 million of funded capital rather than an undrawn facility that may or may not be used. The proceeds have been settled, meaning interest costs begin regardless of how quickly the company deploys the money.

This creates a capital-allocation clock. Holding the proceeds in cash preserves optionality but produces a negative carrying cost if investment returns remain below the cost of borrowing. Deploying the funds rapidly reduces that drag but could weaken acquisition discipline.

The Acorda transaction provides a relevant reference point. At $185 million, it was considerably smaller than the new Schuldschein and added marketed neurology products rather than an early-stage research portfolio. A transaction of that type can contribute revenue immediately, although integration, commercial investment and product performance still determine the eventual return.

The €450 million financing could support one substantial acquisition, several smaller transactions or a mixture of organic investment and refinancing. Merz has not committed to any of these scenarios.

The strongest outcome would be disciplined deployment into assets that complement existing commercial platforms and generate sufficient cash flow to service the debt. The weaker outcome would involve paying high acquisition multiples, assuming significant development risk or allowing the proceeds to remain underutilised for an extended period.

Which financial milestones will show whether Merz is using the €450 million productively?

The first milestone will be clarity on capital deployment. A future acquisition announcement should specify the purchase price, financing mix, expected strategic contribution and integration requirements.

The second will be evidence of earnings and cash-flow growth. Revenue expansion alone will not establish value creation if margins weaken or working-capital demands absorb the additional cash.

Merz’s next financial communication would be more informative if it disclosed net debt, operating cash generation and the weighted average cost of the Schuldschein. Those measures would allow stakeholders to assess whether the group’s financing burden remains proportionate to its operating performance.

The performance of INBRIJA and (F)AMPYRA will also provide evidence about Merz Therapeutics’ ability to integrate acquired products and expand them through its international infrastructure. Successful execution would strengthen the case for using the new capital on further specialty-neurology assets.

The financing has already improved Merz’s access to long-term capital and broadened its institutional lender base. What remains unresolved is whether management can convert that flexibility into returns exceeding the interest, integration and execution costs. The decisive proof point will be cash-flow growth from the investments funded or enabled by the €450 million proceeds.

What are the key takeaways from Merz Group’s €450 million Schuldschein financing?

• Merz completed its first Schuldschein with a final volume of €450 million.
• The transaction was launched at €150 million before strong demand allowed the amount to triple.
• Approximately 50 German and international institutional investors participated.
• The financing includes fixed- and floating-rate tranches with maturities of three, five, seven and ten years.
• Merz achieved a credit spread below 100 basis points on the five-year benchmark tranche.
• The proceeds have been paid out and complement the group’s syndicated financing.
• Merz intends to use the additional flexibility for organic and inorganic growth.
• The company has not disclosed the all-in borrowing cost, current leverage or detailed allocation of proceeds.
• The maturity ladder reduces concentration, but the size of each tranche remains unknown.
• Future cash-flow growth and acquisition returns will determine whether the financing creates economic value.